- Question 1
- Question 2
- Question 3
- Question 4
- Question 5
Castleman disease is a lymphoproliferative disorder involving an overgrowth of lymphatic cells, and affects nearly 5,000 patients annually. Multicentric Castleman Disease (MCD) affects multiple lymph nodes and lymphatic tissue. Symptoms commonly include night sweats, fevers, fatigue, and enlarged liver or spleen.
Current treatment options for MCD include surgery, chemotherapy and/or radiation therapy.
SYLVANTŪ (siltuximab) is indicated for the treatment of patients with Multicentric Castleman`s Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of use: SYLVANTŪ was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANTŪ did not bind to virally produced interleukin-6 (IL-6) in a nonclinical study.